{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:26:38Z","timestamp":1793143598190,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metabolomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Exploiting the full potential of neoadjuvant treatment (NAT) in pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of biomarkers for treatment response. Dysregulated lipid metabolism has been suggested to promote PDAC growth and resistance to therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate lipid metabolic changes in PDAC following NAT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cross-sectional study of mass spectrometry-based global lipidomic profiling of tumour tissue (n\u2009=\u200935) and paired serum samples (n\u2009=\u200935) from treatment-na\u00efve (TN; n\u2009=\u200918) and neoadjuvant FOLFIRINOX-treated (NAT; n\u2009=\u200917) PDAC patients was conducted. Pre- and post-treatment CA 19\u20139 levels were available from 15 NAT patients. Differentially abundant lipids (DALs) in NAT versus TN were assessed for correlation with various clinical parameters and the performance of all serum DALs to distinguish NAT from TN samples was explored using receiver operating characteristic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 40 tissue and 35 serum DALs were identified, which mainly belonged to glycerophospholipids and sphingolipids in tissue and glycerolipids, glycerophospholipids, and fatty acyls in serum. All 19 serum glycerolipids were less abundant in NAT and 18 of these were triacylglycerols. The abundance of 26 tissue and 11 serum DALs correlated moderately with % reduction in serum CA 19\u20139 following NAT. The top five of 23 serum DALs with moderate discriminatory potential (AUC\u2009=\u20090.66\u20130.87) \u2012 PI(18:0_20:3), AcCa(13:0), PC(O-42:6), TG(49:6), TG(66:14), performed better together (AUC\u2009=\u20090.93 and 95% CI\u2009=\u20090.79\u20121) and combined with CA 19\u20139 (AUC\u2009=\u20090.99 and 95% CI\u2009=\u20090.81\u20121).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both tumour tissue and serum samples from PDAC patients showed lower abundance of lipid metabolites following neoadjuvant FOLFIRINOX treatment. Moreover, a biomarker panel of CA 19\u20139 together with five serum DALs could potentially be used to assess NAT response in PDAC but requires further validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11306-025-02388-z","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:53:10Z","timestamp":1768816390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduced lipid metabolite abundance in human pancreatic cancer and matched serum samples following neoadjuvant FOLFIRINOX treatment"],"prefix":"10.1007","volume":"22","author":[{"given":"Manoj","family":"Amrutkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander Johannes Thorbj\u00f8rnsen","family":"Guttorm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut J\u00f8rgen","family":"Labori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Rootwelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja Benedikte Prest\u00f8","family":"Elgst\u00f8en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar P.","family":"Gladhaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S.","family":"Verbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"9","key":"2388_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.70009","volume":"4","author":"HBR Alabed","year":"2024","unstructured":"Alabed, H. B. R., Mancini, D. F., Buratta, S., Calzoni, E., Giacomo, D. D., Emiliani, C., et al. (2024). LipidOne 2.0: A web tool for discovering biological meanings hidden in lipidomic data. Current Protocols, 4(9), Article e70009.","journal-title":"Current Protocols"},{"issue":"2","key":"2388_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/1878-0261.13759","volume":"19","author":"M Amrutkar","year":"2025","unstructured":"Amrutkar, M., Guttorm, S. J. T., Finstadsveen, A. V., Labori, K. J., Eide, L., Rootwelt, H., et al. (2025). Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer. Molecular Oncology, 19(2), 391\u2013411.","journal-title":"Molecular Oncology"},{"issue":"1","key":"2388_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/1878-0261.13344","volume":"17","author":"M Amrutkar","year":"2023","unstructured":"Amrutkar, M., Verbeke, C. S., Finstadsveen, A. V., Dorg, L., Labori, K. J., & Gladhaug, I. P. (2023). Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma. Molecular Oncology, 17(1), 59\u201381.","journal-title":"Molecular Oncology"},{"key":"2388_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11030151","author":"MR Belhaj","year":"2021","unstructured":"Belhaj, M. R., Lawler, N. G., & Hoffman, N. J. (2021). Metabolomics and lipidomics: Expanding the molecular landscape of exercise biology. Metabolites. https:\/\/doi.org\/10.3390\/metabo11030151","journal-title":"Metabolites"},{"key":"2388_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116429","volume":"251","author":"J Bogusiewicz","year":"2024","unstructured":"Bogusiewicz, J., Kupcewicz, B., Wnuk, K., Gaca-Tabaszewska, M., Furtak, J., Harat, M., et al. (2024). The impact of sampling time point on the lipidome composition. Journal of Pharmaceutical and Biomedical Analysis, 251, Article 116429.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"19","key":"2388_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T., Desseigne, F., Ychou, M., Bouch\u00e9, O., Guimbaud, R., B\u00e9couarn, Y., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine, 364(19), 1817\u20131825.","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"2388_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O\u2019Reilly, E. M., et al. (2023). Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(11), 987\u20131002.","journal-title":"Annals of Oncology"},{"issue":"6","key":"2388_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.molmed.2024.03.008","volume":"30","author":"MC De Santis","year":"2024","unstructured":"De Santis, M. C., Bockorny, B., Hirsch, E., Cappello, P., & Martini, M. (2024). Exploiting pancreatic cancer metabolism: Challenges and opportunities. Trends in Molecular Medicine, 30(6), 592\u2013604.","journal-title":"Trends in Molecular Medicine"},{"issue":"14","key":"2388_CR9","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1002\/1878-0261.13216","volume":"16","author":"C Diaz","year":"2022","unstructured":"Diaz, C., Gonzalez-Olmedo, C., Diaz-Beltran, L., Camacho, J., Mena Garcia, P., Martin-Blazquez, A., et al. (2022). Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: A novel metabolomics approach. Molecular Oncology, 16(14), 2658\u20132671.","journal-title":"Molecular Oncology"},{"issue":"5","key":"2388_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1194\/jlr.E400004-JLR200","volume":"46","author":"E Fahy","year":"2005","unstructured":"Fahy, E., Subramaniam, S., Brown, H. A., Glass, C. K., Merrill, A. H., Jr., Murphy, R. C., et al. (2005). A comprehensive classification system for lipids. Journal of Lipid Research, 46(5), 839\u2013861.","journal-title":"Journal of Lipid Research"},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1194\/jlr.R800095-JLR200","volume":"50","author":"E Fahy","year":"2009","unstructured":"Fahy, E., Subramaniam, S., Murphy, R. C., Nishijima, M., Raetz, C. R., Shimizu, T., et al. (2009). Update of the LIPID MAPS comprehensive classification system for lipids. Journal of Lipid Research, 50, S9-14.","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"2388_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-024-01956-w","volume":"27","author":"Z Fang","year":"2025","unstructured":"Fang, Z., Ren, G., Ke, S., Xu, Q., Chen, Y., Shi, X., et al. (2025). Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: A retrospective longitudinal study. Breast Cancer Research, 27(1), 2.","journal-title":"Breast Cancer Research"},{"key":"2388_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrad137","author":"I Farnes","year":"2023","unstructured":"Farnes, I., Kleive, D., Verbeke, C. S., Aabakken, L., Issa-Epe, A., Smastuen, M. C., et al. (2023). Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: Real-world data from a population-based, prospective cohort study (NORPACT-2). BJS Open. https:\/\/doi.org\/10.1093\/bjsopen\/zrad137","journal-title":"BJS Open"},{"issue":"1","key":"2388_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mco2.27","volume":"2","author":"Y Fu","year":"2021","unstructured":"Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., et al. (2021). Lipid metabolism in cancer progression and therapeutic strategies. MedComm, 2(1), 27\u201359.","journal-title":"MedComm"},{"issue":"1","key":"2388_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13304-021-01186-1","volume":"74","author":"J Gugenheim","year":"2022","unstructured":"Gugenheim, J., Crovetto, A., & Petrucciani, N. (2022). Neoadjuvant therapy for pancreatic cancer. Updates in Surgery, 74(1), 35\u201342.","journal-title":"Updates in Surgery"},{"issue":"10","key":"2388_CR16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/ijc.34208","volume":"151","author":"P Guo","year":"2022","unstructured":"Guo, P., Teng, T., Liu, W., Fang, Y., Wei, B., Feng, J., et al. (2022). Metabolomic analyses redefine the biological classification of pancreatic cancer and correlate with clinical outcomes. International Journal of Cancer, 151(10), 1835\u20131846.","journal-title":"International Journal of Cancer"},{"key":"2388_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2025.344426","volume":"1371","author":"SJT Guttorm","year":"2025","unstructured":"Guttorm, S. J. T., Wilson, S. R. H., Amundsen, E. K., Rootwelt, H., & Elgstoen, K. B. P. (2025). Scheduled data-dependent acquisition MS provides enhanced identification and sensitivity in clinical lipidomics. Analytica Chimica Acta, 1371, Article 344426.","journal-title":"Analytica Chimica Acta"},{"issue":"11","key":"2388_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrendo.2016.98","volume":"12","author":"X Han","year":"2016","unstructured":"Han, X. (2016). Lipidomics for studying metabolism. Nature Reviews Endocrinology, 12(11), 668\u2013679.","journal-title":"Nature Reviews Endocrinology"},{"key":"2388_CR19","unstructured":"Herink MC. (2000) Medication induced changes in lipids and lipoproteins. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., (eds.) Endotext. South dartmouth (MA)."},{"issue":"1","key":"2388_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/his.15190","volume":"85","author":"MB Holm","year":"2024","unstructured":"Holm, M. B., Lenggenhager, D., Detlefsen, S., Santha, P., & Verbeke, C. S. (2024). Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific criteria. Histopathology, 85(1), 171\u2013181.","journal-title":"Histopathology"},{"issue":"3","key":"2388_CR21","doi-asserted-by":"publisher","first-page":"102923","DOI":"10.1016\/j.jbc.2023.102923","volume":"299","author":"K Horejsi","year":"2023","unstructured":"Horejsi, K., Jin, C., Vankova, Z., Jirasko, R., Strouhal, O., Melichar, B., et al. (2023). Comprehensive characterization of complex glycosphingolipids in human pancreatic cancer tissues. Journal of Biological Chemistry, 299(3), 102923.","journal-title":"Journal of Biological Chemistry"},{"issue":"9","key":"2388_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101194","volume":"4","author":"E Irajizad","year":"2023","unstructured":"Irajizad, E., Kenney, A., Tang, T., Vykoukal, J., Wu, R., Murage, E., et al. (2023). A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Reports Medicine, 4(9), Article 101194.","journal-title":"Cell Reports Medicine"},{"issue":"1","key":"2388_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/bjs\/znac350","volume":"110","author":"BV Janssen","year":"2022","unstructured":"Janssen, B. V., van Roessel, S., van Dieren, S., de Boer, O., Adsay, V., Basturk, O., et al. (2022). Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: International interobserver study (ISGPP-1). The British Journal of Surgery, 110(1), 67\u201375.","journal-title":"The British Journal of Surgery"},{"key":"2388_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103332","volume":"66","author":"AE Kaoutari","year":"2021","unstructured":"Kaoutari, A. E., Fraunhoffer, N. A., Hoare, O., Teyssedou, C., Soubeyran, P., Gayet, O., et al. (2021). Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. eBioMedicine, 66, Article 103332.","journal-title":"eBioMedicine"},{"issue":"1","key":"2388_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros, N., & Poulogiannis, G. (2020). Reprogramming of fatty acid metabolism in cancer. British Journal of Cancer, 122(1), 4\u201322.","journal-title":"British Journal of Cancer"},{"key":"2388_CR26","unstructured":"Lawrence J. Burgart CS, N. Volkan Adsay, Patrick Fitzgibbons, Wendy L. Frankel, David S. Klimstra, Sanjay Kakar, Alyssa M. Krasinskas, Mari Mino-Kenudson, Timothy Pawlik, Jean-Nicolas Vauthey, Mary K. (2020). Washington protocol for the examination of specimens from patients with carcinoma of the pancreas: College of American Pathologists (CAP) [4.1.0.0]"},{"issue":"1","key":"2388_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12935-023-03138-8","volume":"23","author":"Y Li","year":"2023","unstructured":"Li, Y., Amrutkar, M., Finstadsveen, A. V., Dalen, K. T., Verbeke, C. S., & Gladhaug, I. P. (2023). Fatty acids abrogate the growth-suppressive effects induced by inhibition of cholesterol flux in pancreatic cancer cells. Cancer Cell International, 23(1), 276.","journal-title":"Cancer Cell International"},{"issue":"6","key":"2388_CR28","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1194\/jlr.M033506","volume":"54","author":"G Liebisch","year":"2013","unstructured":"Liebisch, G., Vizcaino, J. A., Kofeler, H., Trotzmuller, M., Griffiths, W. J., Schmitz, G., et al. (2013). Shorthand notation for lipid structures derived from mass spectrometry. Journal of Lipid Research, 54(6), 1523\u20131530.","journal-title":"Journal of Lipid Research"},{"key":"2388_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102353","volume":"67","author":"Y Miyashita","year":"2024","unstructured":"Miyashita, Y., Hitsumoto, T., Fukuda, H., Kim, J., Ito, S., Kimoto, N., et al. (2024). Metabolic syndrome is linked to the incidence of pancreatic cancer. EClinicalMedicine, 67, Article 102353.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"2388_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10654-023-01014-3","volume":"38","author":"S Naudin","year":"2023","unstructured":"Naudin, S., Sampson, J. N., Moore, S. C., Albanes, D., Freedman, N. D., Weinstein, S. J., et al. (2023). Lipidomics and pancreatic cancer risk in two prospective studies. European Journal of Epidemiology, 38(7), 783\u2013793.","journal-title":"European Journal of Epidemiology"},{"issue":"1","key":"2388_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/pathophysiology31010013","volume":"31","author":"T Nemkov","year":"2024","unstructured":"Nemkov, T., Cendali, F., Dzieciatkowska, M., Stephenson, D., Hansen, K. C., Jankowski, C. M., et al. (2024). A multiomics assessment of preoperative exercise in pancreatic cancer survivors receiving neoadjuvant therapy: A case series. Pathophysiology, 31(1), 166\u2013182.","journal-title":"Pathophysiology"},{"key":"2388_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fonc.2020.00245","volume":"10","author":"A Oba","year":"2020","unstructured":"Oba, A., Ho, F., Bao, Q. R., Al-Musawi, M. H., Schulick, R. D., & Del Chiaro, M. (2020). Neoadjuvant treatment in pancreatic cancer. Frontiers in Oncology, 10, 245.","journal-title":"Frontiers in Oncology"},{"key":"2388_CR33","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.3390\/nu15163637","volume":"15","author":"T Padro","year":"2023","unstructured":"Padro, T., Lopez-Yerena, A., Perez, A., Vilahur, G., & Badimon, L. (2023). Dietary omega3 fatty acids and phytosterols in the modulation of the HDL lipidome: A longitudinal crossover clinical study. Nutrients, 15, 3637.","journal-title":"Nutrients"},{"key":"2388_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae253","author":"Z Pang","year":"2024","unstructured":"Pang, Z., Lu, Y., Zhou, G., Hui, F., Xu, L., Viau, C., et al. (2024). MetaboAnalyst 6.0: Towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Research. https:\/\/doi.org\/10.1093\/nar\/gkae253","journal-title":"Nucleic Acids Research"},{"issue":"9","key":"2388_CR35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A., & O\u2019Reilly, E. M. (2021). Pancreatic cancer: A review. JAMA, 326(9), 851\u2013862.","journal-title":"JAMA"},{"issue":"6","key":"2388_CR36","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/bioinformatics\/btab867","volume":"38","author":"RM Pellegrino","year":"2022","unstructured":"Pellegrino, R. M., Giulietti, M., Alabed, H. B. R., Buratta, S., Urbanelli, L., Piva, F., et al. (2022). LipidOne: User-friendly lipidomic data analysis tool for a deeper interpretation in a systems biology scenario. Bioinformatics, 38(6), 1767\u20131769.","journal-title":"Bioinformatics"},{"key":"2388_CR37","doi-asserted-by":"publisher","first-page":"342144","DOI":"10.1016\/j.aca.2023.342144","volume":"1288","author":"O Peterka","year":"2024","unstructured":"Peterka, O., Maccelli, A., Jirasko, R., Vankova, Z., Idkowiak, J., Hrstka, R., et al. (2024). HILIC\/MS quantitation of low-abundant phospholipids and sphingolipids in human plasma and serum: Dysregulation in pancreatic cancer. Analytica Chimica Acta, 1288, 342144.","journal-title":"Analytica Chimica Acta"},{"issue":"1","key":"2388_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-020-01169-7","volume":"19","author":"C Qin","year":"2020","unstructured":"Qin, C., Yang, G., Yang, J., Ren, B., Wang, H., Chen, G., et al. (2020). Metabolism of pancreatic cancer: Paving the way to better anticancer strategies. Molecular Cancer, 19(1), 50.","journal-title":"Molecular Cancer"},{"issue":"11","key":"2388_CR39","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research, 74(11), 2913\u20132921.","journal-title":"Cancer Research"},{"issue":"11","key":"2388_CR40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F Rohrig","year":"2016","unstructured":"Rohrig, F., & Schulze, A. (2016). The multifaceted roles of fatty acid synthesis in cancer. Nature Reviews Cancer, 16(11), 732\u2013749.","journal-title":"Nature Reviews Cancer"},{"issue":"4","key":"2388_CR41","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1021\/es5002105","volume":"48","author":"EL Schymanski","year":"2014","unstructured":"Schymanski, E. L., Jeon, J., Gulde, R., Fenner, K., Ruff, M., Singer, H. P., et al. (2014). Identifying small molecules via high resolution mass spectrometry: Communicating confidence. Environmental Science & Technology, 48(4), 2097\u20132098.","journal-title":"Environmental Science & Technology"},{"issue":"1","key":"2388_CR42","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7\u201333.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"2388_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-0716-4116-3_2","volume":"2855","author":"HB Skogvold","year":"2025","unstructured":"Skogvold, H. B., Sand, E. S., & Elgstoen, K. B. P. (2025). Global metabolomics using LC-MS for clinical applications. Methods in Molecular Biology, 2855, 23\u201339.","journal-title":"Methods in Molecular Biology"},{"issue":"1","key":"2388_CR44","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12967-024-05524-w","volume":"22","author":"Y Song","year":"2024","unstructured":"Song, Y., Jiang, L., Han, Y., Zhang, S., & Li, S. (2024). Triglyceride-glucose index and glycemic dynamics in pancreatic ductal adenocarcinoma: Implications for disease progression and prognosis. Journal of Translational Medicine, 22(1), 708.","journal-title":"Journal of Translational Medicine"},{"key":"2388_CR45","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/978-1-0716-1266-8_27","volume":"2276","author":"AL Souza","year":"2021","unstructured":"Souza, A. L., & Patti, G. J. (2021). A protocol for untargeted metabolomic analysis: From sample preparation to data processing. Methods in Molecular Biology, 2276, 357\u2013382.","journal-title":"Methods in Molecular Biology"},{"issue":"5","key":"2388_CR46","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., et al. (2023). Neoadjuvant therapy for pancreatic cancer. Nature Reviews Clinical Oncology, 20(5), 318\u2013337.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"12","key":"2388_CR47","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1002\/ijc.34867","volume":"154","author":"MN Stillger","year":"2024","unstructured":"Stillger, M. N., Kurowski, K., Bronsert, P., Brombacher, E., Kreutz, C., Werner, M., et al. (2024). Neoadjuvant chemo- or chemo-radiation-therapy of pancreatic ductal adenocarcinoma differentially shift ECM composition, complement activation, energy metabolism and ribosomal proteins of the residual tumor mass. International Journal of Cancer, 154(12), 2162\u20132175.","journal-title":"International Journal of Cancer"},{"issue":"20","key":"2388_CR48","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1158\/0008-5472.CAN-16-3062","volume":"77","author":"S Tadros","year":"2017","unstructured":"Tadros, S., Shukla, S. K., King, R. J., Gunda, V., Vernucci, E., Abrego, J., et al. (2017). De novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer. Cancer Research, 77(20), 5503\u20135517.","journal-title":"Cancer Research"},{"issue":"10","key":"2388_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101234","volume":"4","author":"R Tang","year":"2023","unstructured":"Tang, R., Xu, J., Wang, W., Meng, Q., Shao, C., Zhang, Y., et al. (2023). Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Cell Reports Medicine, 4(10), Article 101234.","journal-title":"Cell Reports Medicine"},{"issue":"1","key":"2388_CR50","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1038\/s41598-024-56737-4","volume":"14","author":"T Teng","year":"2024","unstructured":"Teng, T., Shi, H., Fan, Y., Guo, P., Zhang, J., Qiu, X., et al. (2024). Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: Biomarker identification and prognosis prediction. Scientific Reports, 14(1), 6938.","journal-title":"Scientific Reports"},{"issue":"14","key":"2388_CR51","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1007\/s00018-021-03866-y","volume":"78","author":"A Tuerhong","year":"2021","unstructured":"Tuerhong, A., Xu, J., Shi, S., Tan, Z., Meng, Q., Hua, J., et al. (2021). Overcoming chemoresistance by targeting reprogrammed metabolism: The Achilles\u2019 heel of pancreatic ductal adenocarcinoma. Cellular and Molecular Life Sciences, 78(14), 5505\u20135526.","journal-title":"Cellular and Molecular Life Sciences"},{"key":"2388_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","volume":"160","author":"JL van Dam","year":"2022","unstructured":"van Dam, J. L., Janssen, Q. P., Besselink, M. G., Homs, M. Y. V., van Santvoort, H. C., van Tienhoven, G., et al. (2022). Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. European Journal of Cancer, 160, 140\u2013149.","journal-title":"European Journal of Cancer"},{"issue":"6","key":"2388_CR53","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/his.14540","volume":"79","author":"C Verbeke","year":"2021","unstructured":"Verbeke, C., Webster, F., Brosens, L., Campbell, F., Del Chiaro, M., Esposito, I., et al. (2021). Dataset for the reporting of carcinoma of the exocrine pancreas: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 79(6), 902\u2013912.","journal-title":"Histopathology"},{"issue":"18","key":"2388_CR54","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. The New England Journal of Medicine, 369(18), 1691\u20131703.","journal-title":"The New England Journal of Medicine"},{"key":"2388_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101936","volume":"83","author":"N Wajapeyee","year":"2024","unstructured":"Wajapeyee, N., Beamon, T. C., & Gupta, R. (2024). Roles and therapeutic targeting of ceramide metabolism in cancer. Molecular Metabolism, 83, Article 101936.","journal-title":"Molecular Metabolism"},{"issue":"2","key":"2388_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jgg.2019.11.009","volume":"47","author":"R Wang","year":"2020","unstructured":"Wang, R., Li, B., Lam, S. M., & Shui, G. (2020). Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression. Journal of Genetics and Genomics, 47(2), 69\u201383.","journal-title":"Journal of Genetics and Genomics"},{"issue":"1","key":"2388_CR57","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12944-017-0515-5","volume":"16","author":"Y Wang","year":"2017","unstructured":"Wang, Y., & Xu, D. (2017). Effects of aerobic exercise on lipids and lipoproteins. Lipids in Health and Disease, 16(1), 132.","journal-title":"Lipids in Health and Disease"},{"issue":"1","key":"2388_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41467-021-27765-9","volume":"13","author":"D Wolrab","year":"2022","unstructured":"Wolrab, D., Jirasko, R., Cifkova, E., Horing, M., Mei, D., Chocholouskova, M., et al. (2022). Lipidomic profiling of human serum enables detection of pancreatic cancer. Nature Communications, 13(1), 124.","journal-title":"Nature Communications"},{"issue":"8","key":"2388_CR59","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41419-024-06930-0","volume":"15","author":"H Wu","year":"2024","unstructured":"Wu, H., Fu, M., Wu, M., Cao, Z., Zhang, Q., & Liu, Z. (2024). Emerging mechanisms and promising approaches in pancreatic cancer metabolism. Cell Death & Disease, 15(8), 553.","journal-title":"Cell Death & Disease"},{"issue":"12","key":"2388_CR60","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cac2.12360","volume":"42","author":"X Yin","year":"2022","unstructured":"Yin, X., Xu, R., Song, J., Ruze, R., Chen, Y., Wang, C., et al. (2022). Lipid metabolism in pancreatic cancer: Emerging roles and potential targets. Cancer Communications, 42(12), 1234\u20131256.","journal-title":"Cancer Communications"},{"key":"2388_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083716","author":"A Zhakupova","year":"2025","unstructured":"Zhakupova, A., Zeinolla, A., Kokabi, K., Sergazy, S., & Aljofan, M. (2025). Drug resistance: The role of sphingolipid metabolism. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms26083716","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"2388_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12944-024-02426-0","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y., Yang, Z., Liu, Y., Pei, J., Li, R., & Yang, Y. (2025). Targeting lipid metabolism: Novel insights and therapeutic advances in pancreatic cancer treatment. Lipids in Health and Disease, 24(1), 12.","journal-title":"Lipids in Health and Disease"},{"issue":"4","key":"2388_CR63","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1002\/cam4.5296","volume":"12","author":"R Zhao","year":"2023","unstructured":"Zhao, R., Ren, S., Li, C., Guo, K., Lu, Z., Tian, L., et al. (2023). Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Cancer Medicine, 12(4), 5158\u20135171.","journal-title":"Cancer Medicine"},{"issue":"10","key":"2388_CR64","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s00216-019-02241-y","volume":"412","author":"T Zullig","year":"2020","unstructured":"Zullig, T., Trotzmuller, M., & Kofeler, H. C. (2020). Lipidomics from sample preparation to data analysis: A primer. Analytical and Bioanalytical Chemistry, 412(10), 2191\u20132209.","journal-title":"Analytical and Bioanalytical Chemistry"}],"container-title":["Metabolomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-025-02388-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11306-025-02388-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-025-02388-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T14:03:20Z","timestamp":1770300200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11306-025-02388-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1007\/s11306-025-02388-z","relation":{},"ISSN":["1573-3890"],"issn-type":[{"value":"1573-3890","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and the Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Regional Ethics Committee of South-Eastern Norway (REC South-East, project number 2015\/738). Written informed consent to use biomaterials for research purposes was obtained from all patients included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"18"}}